Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury.
Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Additional screening criteria check may apply for qualification:
Provide written informed consent prior to beginning any study procedures
Cervical spinal cord injury that meet all of the following criteria:
Body mass index (BMI) <40
Exclusion criteria
Additional screening criteria check may apply for qualification:
Primary purpose
Allocation
Interventional model
Masking
72 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Clinical Trials Information Desk, to prevent miscommunication,
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal